Day One Biopharmaceuticals Inc

NASDAQ DAWN

Download Data

Day One Biopharmaceuticals Inc Interest Expense To Sales 1 year YoY Change (%) for the quarter ending September 20, 2024

Day One Biopharmaceuticals Inc Interest Expense To Sales 1 year YoY Change (%) is NA for the quarter ending September 20, 2024. The interest expense to sales ratio is a financial metric that represents the proportion of a company's revenue that is used to cover its interest expenses. It is calculated by dividing the company's interest expense by its total revenue. This ratio indicates the financial burden of interest payments on the company's operating income. A higher ratio suggests that a significant portion of the company's revenue is being used to service interest obligations, potentially affecting its profitability. The measure "Change (%)" refers to the percentage change in the value of a financial metric between two time points. This measure provides a relative perspective on the magnitude of change.
NASDAQ: DAWN

Day One Biopharmaceuticals Inc

CEO Dr. Jeremy Bender M.B.A., Ph.D.
IPO Date May 27, 2021
Location United States
Headquarters 395 Oyster Point Boulevard, South San Francisco, CA, United States, 94080
Employees 174
Sector Healthcare
Industry Biotechnology
Description

Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genomically defined cancers. Its lead product candidate is tovorafenib, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric patients with relapsed/ refractory low-grade glioma. The company is also developing Pimasertib, an oral small molecule inhibitor of mitogen-activated protein kinase kinases 1 and 2. Day One Biopharmaceuticals, Inc. was incorporated in 2018 and is headquartered in Brisbane, California.

Similar companies

ABOS

Acumen Pharmaceuticals Inc

NA

NA

ELDN

Eledon Pharmaceuticals Inc

NA

NA

StockViz Staff

September 20, 2024

Any question? Send us an email